RxSight (NASDAQ: RXST) posts wider Q1 loss but keeps 2026 sales outlook

Rhea-AI Filing Summary

RxSight, Inc. reported first quarter 2026 sales of $30.9 million, down 18.5% from a year earlier, mainly due to lower Light Delivery Device volumes, while Light Adjustable Lens procedures decreased 0.4% year over year. Gross profit margin improved to 76.1% from 74.8% on a richer lens mix.

Total operating expenses rose to $41.3 million from $39.0 million as the company expanded its global commercial and support teams. Net loss widened to $15.9 million, or $0.38 per share, versus $8.2 million, or $0.20 per share, with adjusted net loss at $7.9 million, or $0.19 per share. Cash, cash equivalents and short-term investments totaled $217.9 million as of March 31, 2026. RxSight reiterated 2026 revenue guidance of $120 to $135 million and gross margin guidance of 70% to 72%, and now expects operating expenses at the high end of its prior $150 to $160 million range.

Positive

• None.

Negative

• Q1 2026 revenue declined 18.5% year over year to $30.9 million, with Light Adjustable Lens procedures down 0.4%, signaling weaker near-term growth momentum despite product adoption efforts.
• Profitability deteriorated meaningfully, as net loss widened to $15.9 million ($0.38 per share) from $8.2 million ($0.20 per share), and adjusted net loss increased to $7.9 million, indicating rising costs and negative operating leverage.

Insights

Medical devices equity analyst

Revenue declined and losses widened, but full-year sales and margin guidance were reaffirmed.

RxSight delivered Q1 2026 sales of $30.9 million, an 18.5% year-over-year decline, mainly from lower Light Delivery Device units, while Light Adjustable Lens procedures were essentially flat. Despite lower volume, gross profit margin expanded to 76.1%, helped by a higher mix of lens sales.

Operating expenses rose to $41.3 million, up from $39.0 million, reflecting continued commercial and support hiring. Net loss nearly doubled to $15.9 million, or $0.38 per share, and adjusted net loss reached $7.9 million, or $0.19 per share. These figures indicate heavier spending and negative operating leverage on a smaller revenue base.

Management reaffirmed 2026 revenue guidance of $120–$135 million and gross margin of 70–72%, while indicating operating expenses should land at the high end of the prior $150–$160 million range and stock-based compensation of $30–$32 million. With $217.9 million in cash, cash equivalents and short-term investments as of March 31, 2026, the company maintains a sizable liquidity cushion to support growth initiatives.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q1 2026 sales: $30.9 million Q1 2026 gross margin: 76.1% Q1 2026 net loss per share: $0.38 basic and diluted +5 more

8 metrics

Q1 2026 sales $30.9 million Down 18.5% year over year for the quarter ended March 31, 2026

Q1 2026 gross margin 76.1% Improved from 74.8% in the prior-year quarter

Q1 2026 net loss per share $0.38 basic and diluted Net loss of $15.9 million vs $8.2 million, Q1 2026 vs Q1 2025

Q1 2026 adjusted net loss per share $0.19 basic and diluted Adjusted net loss of $7.9 million vs $1.1 million in Q1 2025

Cash and short-term investments $217.9 million Cash, cash equivalents and short-term investments as of March 31, 2026

2026 revenue guidance $120–$135 million Full-year 2026 revenue outlook reiterated

2026 gross margin guidance 70–72% Full-year 2026 gross margin outlook reiterated

2026 operating expense range $150–$160 million (high end expected) Full-year 2026 operating expense expectation

Key Terms

Light Adjustable Lens, Light Delivery Devices, gross profit margin, non-GAAP financial measures, +2 more

6 terms

Light Adjustable Lens medical

"Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units"

A light adjustable lens is an implanted corrective lens for the eye whose focusing power can be noninvasively fine-tuned after surgery by exposing it to patterned light, allowing the lens to be customized to a patient’s vision once healing is complete. For investors, it matters because the technology can reduce follow-up corrective procedures, create a service and consumables ecosystem, and affect adoption and reimbursement dynamics that influence sales growth and margins.

Light Delivery Devices medical

"20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 units"

Light delivery devices are medical tools that guide controlled beams of light into or onto the body to diagnose conditions or activate treatments, such as tiny fiber-optic probes, endoscopic lamps, wearable LED patches or laser applicators. They matter to investors because these devices can enable new, less invasive therapies and diagnostics, influence clinical success and regulatory approval, and open recurring revenue streams—think of them as precision flashlights that make targeted treatments possible.

gross profit margin financial

"First quarter gross profit margin of 76.1% increased from 74.8% in the prior‑year period"

Gross profit margin shows how much money a company keeps from sales after paying for the goods or services it sold. It’s like checking how much profit is left over from each dollar earned before covering other costs. A higher margin indicates the company makes more money from its sales, which helps assess its profitability and efficiency.

non-GAAP financial measures financial

"To supplement our unaudited condensed consolidated financial statements... we believe certain non-GAAP measures"

Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.

stock-based compensation financial

"For example, we exclude stock-based compensation expense because this expense is non-cash in nature"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

adjusted net loss financial

"Adjusted net loss in the first quarter of 2026 was $(7.9) million"

Adjusted net loss is the company’s reported net loss after removing one-time, non-cash, or unusual items that management says obscure underlying results, such as restructuring charges, asset write-downs, or stock-based pay. Investors use it to focus on the business’s core profitability — like smoothing out potholes to judge road quality — but should be cautious because choices about what to exclude can make performance look better than it really is.

Offering Details

earnings_snapshot

Offering

Offering Type earnings_snapshot

Understanding 8-K Material Events →

0001111485false00011114852026-05-062026-05-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 06, 2026

RxSight, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40690	94-3268801
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California				92656
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (949) 521-7830

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		RXST		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 6, 2026, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

The following exhibit is furnished as part of this report:

Exhibit number		Description
99.1		Press Release dated May 6, 2026.
104		Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			RxSight, Inc.
Date:	May 6, 2026	By:	/s/ Mark Wilterding
			Name: Mark Wilterding Title: Chief Financial Officer

Exhibit 99.1

RXSIGHT, INC. REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES FULL-YEAR SALES OUTLOOK

Aliso Viejo, Calif. – May 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026.

Strategic Highlights and Recent Developments

•Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units

•20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 units

•Robust clinical data presented at the recent American Society of Cataract and Refractive Surgery (ASCRS) annual meeting highlighting the versatility and impact of adjustability

•Recent regulatory approval in New Zealand furthering the company’s international footprint and global market opportunity

•2026 sales and gross margin guidance unchanged; operating expense expected to be at high end of previous range reflecting targeted investments in strategic growth initiatives

“We are encouraged by the stabilizing business trends and the initial progress from our ongoing commercial initiatives,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “As we continue to refine these efforts, investing in both our team and our pipeline, we are confident that we can continue to build momentum across the company and reach the full potential of our technology for patients and practices.”

First Quarter Financial Results

In the first quarter of 2026, the company reported sales of $30.9 million, down 18.5% compared to the prior year, largely reflecting lower LDD unit volumes, consistent with expectations. LAL procedures decreased 0.4% year over year.

First quarter gross profit margin of 76.1% increased from 74.8% in the prior‑year period, primarily driven by a favorable shift in product mix toward LAL sales.

Total operating expenses were $41.3 million versus $39.0 million in the year-ago period. The increase was primarily driven by the continued expansion of our global commercial and support teams.

In the first quarter of 2026, the company reported a net loss of $(15.9) million, or $(0.38) per basic and diluted share, compared to a net loss of $(8.2) million, or $(0.20) per basic and diluted share in the first quarter of 2025. Adjusted net loss in the first quarter of 2026 was $(7.9) million, or $(0.19) per basic and diluted share, compared to an adjusted net loss of $(1.1) million, or $(0.03) per basic and diluted share in the first quarter of 2025.

As of March 31, 2026, cash, cash equivalents and short-term investments totaled $217.9 million.

2026 ASCRS Highlights

At the recent ASCRS annual meeting, RxSight technology was featured across multiple scientific presentations addressing refractive accuracy, complex cases and evolving treatment strategies. This rapidly expanding body of clinical evidence highlighted both the versatility and impact of adjustability. In addition, the conference included presentations by Dr. Szabo, who reported binocular LAL outcomes in which 93.1% of patients achieved simultaneous 20/20 or better distance and J1 or better near, as well as a meta-analysis by Dr. Rabinovitch, demonstrating pooled accuracy with the LAL was 91.2% within 0.50 diopters of target refraction.

2026 Guidance

The company’s 2026 financial guidance is as follows:

•Revenue of $120 to $135 million, in-line with previous guidance

•Gross margin of 70% to 72%, in-line with previous guidance

•Operating expenses expected to be at the high-end of previous $150 to $160 million range

•Non-cash stock-based compensation expense of $30 to $32 million, in-line with previous guidance

Conference Call

On Wednesday, May 6, 2026, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its first quarter 2026 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 2630350. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL/LAL+, collectively the “LAL”), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Forward-Looking Statements

This press release contains forward-looking statements, including: including statements regarding the company’s expectations related to stabilizing business trends; the initial progress from its ongoing

commercial initiatives; ongoing refinement of its commercial efforts; continued investments in its team and pipeline; its ability to build momentum across the company; and its ability to reach the full potential of its technology for patients and practices. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the three months ended March 31, 2026, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

RxSight, Inc., the RxSight Light Adjustable Lens LAL, LAL+, and LDD are trademarks of RxSight, Inc.

Investor Relations Contact:

Oliver Moravcevic

VP, Investor Relations

omoravcevic@rxsight.com

RxSight, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS (UNAUDITED)

(In thousands, except share and per share amounts)

		Three Months Ended March 31,
		2026				2025
Sales		$	30,893			$	37,895
Cost of sales			7,395				9,566
Gross profit			23,498				28,329
Operating expenses:
Selling, general and administrative			31,855				28,636
Research and development			9,472				10,367
Total operating expenses			41,327				39,003
Loss from operations			(17,829	)			(10,674	)
Other income (expense), net:
Interest expense			(3	)			(6	)
Interest and other income			1,954				2,508
Loss before income taxes			(15,878	)			(8,172	)
Income tax expense			6				18
Net loss		$	(15,884	)		$	(8,190	)
Other comprehensive loss
Unrealized loss on short-term investments			(120	)			(157	)
Foreign currency translation gain			—				6
Total other comprehensive loss			(120	)			(151	)
Comprehensive loss		$	(16,004	)		$	(8,341	)
Net loss per share:
Basic & diluted		$	(0.38	)		$	(0.20	)
Weighted-average shares used in computing net loss per share:
Attributable to common stock, basic & diluted			41,306,110				40,509,646

RxSight, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(In thousands, except share and per share amounts)

		March 31,				December 31,
		2026				2025
		(Unaudited)
Assets
Current assets:
Cash and cash equivalents		$	17,573			$	19,949
Short-term investments			200,307				208,179
Accounts receivable, net			22,443				23,383
Inventories, net			34,869				31,559
Prepaid and other current assets			4,032				4,389
Total current assets			279,225				287,459
Property and equipment, net			13,232				13,056
Operating leases right-of-use assets			9,760				9,959
Restricted cash			750				750
Other assets			1,026				590
Total assets		$	303,993			$	311,814
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	7,124			$	5,296
Accrued expenses and other current liabilities			18,748				19,795
Lease liabilities			1,504				1,162
Total current liabilities			27,376				26,253
Long-term lease liabilities			9,322				9,878
Other long-term liabilities			—				—
Total liabilities			36,698				36,131
Commitments and contingencies
Stockholders' equity:
Common stock, $0.001 par value, 900,000,000 shares authorized,   41,384,120 shares issued and outstanding as of March 31, 2026 and   41,242,005 shares issued and outstanding as of December 31, 2025			41				41
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued   and outstanding			—				—
Additional paid-in capital			944,244				936,628
Accumulated other comprehensive (loss) income			(67	)			53
Accumulated deficit			(676,923	)			(661,039	)
Total stockholders' equity			267,295				275,683
Total liabilities and stockholders' equity		$	303,993			$	311,814

Non-GAAP Financial Measures

To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including adjusted net earnings (loss), and adjusted net earnings (loss) per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because this expense is non-cash in nature and we believe excluding this item provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.

We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Net Earnings (Loss) and Adjusted Net Earnings (Loss) Per Share

Adjusted net earnings (loss) is a non-GAAP financial measure that we define as net earnings (loss) adjusted for stock-based compensation. We believe adjusted net earnings (loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

Reconciliations of net earnings (loss) to adjusted net earnings (loss) and the presentation of adjusted net earnings (loss) per share, basic and diluted, are as follows:

		Three months ended March 31,
		2026				2025
Common Stock
Numerator:
Net loss available to stockholders, basic and diluted		$	(15,884	)		$	(8,190	)
Add:
Stock-based compensation			7,945				7,140
Adjusted net loss available to common stockholders, basic and diluted:		$	(7,939	)		$	(1,050	)
Denominator:
Weighted-average shares outstanding, basic and diluted			41,306,110				40,509,646
Adjusted net loss per share, basic and diluted		$	(0.19	)		$	(0.03	)

FAQ

How did RxSight (RXST) perform financially in Q1 2026?

RxSight reported Q1 2026 sales of $30.9 million, down 18.5% year over year, and a net loss of $15.9 million, or $0.38 per share. Adjusted net loss was $7.9 million, or $0.19 per share, reflecting higher operating expenses and lower Light Delivery Device volume.

What were RxSight (RXST) gross margin and operating expenses in Q1 2026?

Gross profit margin in Q1 2026 was 76.1%, up from 74.8% a year earlier, mainly due to a favorable product mix toward Light Adjustable Lens sales. Total operating expenses rose to $41.3 million from $39.0 million, driven by expansion of global commercial and support teams.

What 2026 financial guidance did RxSight (RXST) provide?

For 2026, RxSight guided to revenue of $120–$135 million and a gross margin of 70–72%. The company expects operating expenses at the high end of its prior $150–$160 million range and projects non-cash stock-based compensation of $30–$32 million.

What is RxSight (RXST)’s cash position as of March 31, 2026?

As of March 31, 2026, RxSight held $217.9 million in cash, cash equivalents and short-term investments. This liquidity supports ongoing R&D, commercial expansion and other strategic initiatives while the company continues to operate at a net loss.

How did RxSight (RXST) Light Adjustable Lens and device volumes trend in Q1 2026?

In Q1 2026, RxSight sold 27,472 Light Adjustable Lens units and 20 Light Delivery Devices, bringing the installed base to 1,154 devices. LAL procedures decreased 0.4% year over year, while lower device volume contributed to the overall revenue decline.

What non-GAAP results did RxSight (RXST) report for Q1 2026?

RxSight reported adjusted net loss of $7.9 million, or $0.19 per share, in Q1 2026, compared with adjusted net loss of $1.1 million, or $0.03 per share, in Q1 2025. Adjustments primarily exclude non-cash stock-based compensation expense.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 286.8 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 23.3 KB